According to a new report from the Institute for Clinical and Economic Review (ICER) on the affordability of obesity drugs, compounding is not likely to be a solution to concerns about access and affordability for GLP-1 receptor agonists, especially in obesity.
Compounding Unlikely To Solve GLP-1 Affordable Access Issues
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.
More from Alimentary/Metabolic
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
• By
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.
• By
Adstiladrin sales hit €70m in first full year on the market